BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17152269)

  • 1. Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions.
    Sivertsen S; Berner A; Michael CW; Bedrossian C; Davidson B
    Acta Cytol; 2006; 50(6):603-7. PubMed ID: 17152269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B; Baekelandt M; Shih IeM
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression.
    Sivertsen S; Hadar R; Elloul S; Vintman L; Bedrossian C; Reich R; Davidson B
    Lung Cancer; 2006 Dec; 54(3):309-17. PubMed ID: 16996643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
    Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
    Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
    J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
    Davidson B; Zhang Z; Kleinberg L; Li M; Flørenes VA; Wang TL; Shih IeM
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5944-50. PubMed ID: 17062665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
    Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
    Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.
    Bock AJ; Nymoen DA; Brenne K; Kærn J; Davidson B
    Hum Pathol; 2012 May; 43(5):669-74. PubMed ID: 21855113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinases-2 and -9 by cells isolated from the peritoneal fluid of women with ovarian carcinoma.
    Sakata K; Shigemasa K; Uebaba Y; Nagai N; Ohama K
    Acta Cytol; 2002; 46(4):697-703. PubMed ID: 12146034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.
    Brusegard K; Stavnes HT; Nymoen DA; Flatmark K; Trope CG; Davidson B
    Virchows Arch; 2012 Feb; 460(2):193-202. PubMed ID: 22249560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology.
    Malle D; Valeri RM; Photiou C; Kaplanis K; Andreadis C; Tsavdaridis D; Destouni C
    Acta Cytol; 2005; 49(1):11-6. PubMed ID: 15717748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cadherin switching in ovarian cancer progression.
    Patel IS; Madan P; Getsios S; Bertrand MA; MacCalman CD
    Int J Cancer; 2003 Aug; 106(2):172-7. PubMed ID: 12800191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
    Reich R; Vintman L; Nielsen S; Kaern J; Bedrossian C; Berner A; Davidson B
    Diagn Cytopathol; 2005 Nov; 33(5):332-7. PubMed ID: 16240397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and localization of e-cadherin in epithelial ovarian cancer.
    Koensgen D; Freitag C; Klaman I; Dahl E; Mustea A; Chekerov R; Braicu I; Lichtenegger W; Sehouli J
    Anticancer Res; 2010 Jul; 30(7):2525-30. PubMed ID: 20682978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping.
    Sigstad E; Dong HP; Nielsen S; Berner A; Davidson B; Risberg B
    Diagn Cytopathol; 2005 Nov; 33(5):325-31. PubMed ID: 16240402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells.
    Davidson B; Xi Z; Saatcioglu F
    Diagn Cytopathol; 2007 Feb; 35(2):80-4. PubMed ID: 17230566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma.
    Davidson B; Risberg B; Berner A; Bedrossian CW; Reich R
    Semin Diagn Pathol; 2006 Feb; 23(1):35-43. PubMed ID: 17044194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.